Keywords: morphosys, revenues, leap, 1st, qtr, german, drug
MorphoSys revenues leap 72% in 1st qtr
Article | 09 May 2005
German drug discovery firm MorphoSys AG saw first-quarter 2005 revenues leap 72% to 7.4 million euros ($9.6 million), with growth driven by the therapeutic ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- US FDA advisory panel backs approval of Merck & Co's suvorexant, but only at lower doses
- Italy's pharma market slump set to continue, warns GlobalData
- Is failure to adopt business process management putting the pharma industry at risk?
